SCHEMBL2322787

SCHEMBL2322787

CCOC(=O)C(Br)COC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
TRPA1 O75762 1/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.39
ZDHHC7 Q9NXF8 1/20 0.38
ALOX15 P16050 3/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
TDP1 Q9NUW8 3/20 0.33
TSHR P16473 3/20 0.33
CYP3A4 P08684 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CHRM1 P11229 1/20 0.33
ADORA1 P30542 1/20 0.33
PIN1 Q13526 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7985624 0.84 ALDH1A1 (0.42) ALDH1A1TRPA1HSD17B10LMNAZDHHC7
SCHEMBL15670391 0.81
SCHEMBL2318914 0.81
SCHEMBL1732642 0.78
SCHEMBL1286734 0.78 ALDH1A1 (0.46) ALDH1A1TRPA1HSD17B10LMNAZDHHC7
SCHEMBL240521 0.78 ZDHHC7 (0.47) ALDH1A1TRPA1HSD17B10LMNAZDHHC7
SCHEMBL14016338 0.78 ALDH1A1 (0.46) ALDH1A1TRPA1HSD17B10LMNAZDHHC7
SCHEMBL36999 0.78 ZDHHC7 (0.47) ALDH1A1TRPA1HSD17B10LMNAZDHHC7
SCHEMBL1732696 0.78
SCHEMBL189345 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4524139-A1 IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE Shanghai Simr Biotechnology Co., Ltd. (CN) 2025-03-19 EP disclosed
CN-117069725-A Imidazopyridazine substituted benzene ring derivative, preparation method, pharmaceutical composition and application 上海赛默罗生物科技有限公司 2023-11-17 CN disclosed
WO-2023216753-A1 IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE 上海赛默罗生物科技有限公司 2023-11-16 WO disclosed
US-8946476-B2 Process for the preparation of amino acid derivatives UCB PHARMA GMBH (DE) 2015-02-03 US disclosed
EP-2352721-B1 NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES UCB PHARMA GMBH (DE) 2013-03-27 EP disclosed
US-20110263899-A1 Novel Process for the Preparation of Amino Acid Derivatives UCB PHARMA GMBH (DE) 2011-10-27 US disclosed
EP-2352721-A1 NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES UCB Pharma GmbH (DE) 2011-08-10 EP disclosed
WO-2010052011-A1 NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES UCB PHARMA, S.A. (BE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263899-A1 Novel Process for the Preparation of Amino Acid Derivatives BCAT2, DNPEP, NPEPPS ALDH1A1 2432/4885TRPA1 1787/4885HSD17B10 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.